Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Explore this paper's citation graph
Summary
Multiple myeloma accounts for approximately 10% of hematologic malignancies in the United States and is the second most common cancer in women.
- Type
- article
- Published
- 2013-03-01
- Cited by
- 126
- References
- 126
- Access
- Open access
- OpenAlex
- https://openalex.org/W1969282676
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205295357
Keywords
Multiple myeloma, Medicine, Lenalidomide, Bortezomib, Regimen
References
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
- Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
- Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
- Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
- Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
- Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- Single versus double autologous stem-cell transplantation for multiple myeloma.
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
- Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
- Clinical course of patients with relapsed multiple myeloma.
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
- Identification of a Primary Target of Thalidomide Teratogenicity
Cited by
- The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM
- Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors
- Age‐related health care disparities in multiple myeloma
- Copper-zinc superoxide dismutase and glucose metabolism as redox targets for bortezomib resistance in multiple myeloma
- Multiple myeloma: from diagnosis to treatment.
- Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche
- Les facteurs de transcription MAF dans l’oncogenèse : implication de NRL dans le médulloblastome
- Primer caso descrito de parálisis aislada, completa y fluctuante del III nervio craneal como forma de inicio de un mieloma múltiple
- Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma
- Zielgerichtete Therapien bei hämatologischen Erkrankungen
- Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
- Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
- Malignant lymphoma of the conjunctiva.
- Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study
- Well Plate-Based Perfusion Culture Device for Tissue and Tumor Microenvironment Replication
- Can genome array screening replace FISH as a front‐line test in multiple myeloma?
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
- GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
- Treatment options for myeloma.
Related papers
- Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies
- Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
- Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
- Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
- Lenalidomide: the emerging role of a novel targeted agent in malignancies.
- Mechanism of action of lenalidomide in hematological malignancies
- [Action mechanism of lenalidomide in hematological malignancies - review].
- New Immunomodulatory Drugs in Myeloma
- Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients.
- The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea